Related Experiment Video

Updated: Aug 2, 2026

A Rat Model of Ventricular Fibrillation and Resuscitation by Conventional Closed-chest Technique
09:47

A Rat Model of Ventricular Fibrillation and Resuscitation by Conventional Closed-chest Technique

Published on: April 26, 2015

Carvedilol: a nonselective beta blocking agent with antioxidant properties

Wendy M Book1

  • 1Emory University School of Medicine, Department of Medicine, Division of Cardiology, Atlanta, GA 30322, USA. Wendy_Book@Emoryhealthcare.org

Congestive Heart Failure (Greenwich, Conn.)
|June 5, 2002
PubMed

Insights

Beta blockers, like carvedilol, show promise in managing congestive heart failure by slowing disease progression and reducing mortality. Carvedilol offers additional antioxidant benefits, crucial for combating oxidative stress in heart conditions.

Area of Science:

  • Cardiology
  • Pharmacology
  • Biomedical Science

Background:

  • Congestive heart failure (CHF) remains a significant public health concern with high mortality and morbidity rates.
  • Recent clinical trials highlight the benefits of beta blockers in mitigating CHF progression and mortality.
  • Oxidative stress is a key factor in the advancement of conditions like post-myocardial reperfusion injury and dilated cardiomyopathy.

Purpose of the Study:

  • To evaluate the role of carvedilol, a non-selective beta blocker, in managing congestive heart failure.
  • To highlight the antioxidant properties of carvedilol and their contribution to managing CHF.
  • To underscore the therapeutic potential of carvedilol in light of its dual action.

Main Methods:

  • Review of recent large clinical trials on beta blockers for CHF.
  • Analysis of studies investigating the impact of oxidative stress on heart conditions.
  • Examination of the pharmacological profile of carvedilol, including its beta-blocking and antioxidant effects.

Main Results:

  • Beta blockers have demonstrated efficacy in slowing CHF progression and reducing mortality.
  • Carvedilol possesses significant antioxidant properties, in addition to its beta-blocking activity.
  • These combined effects make carvedilol a valuable therapeutic option for CHF patients.

Conclusions:

  • Carvedilol is an effective non-selective beta blocker for treating congestive heart failure.
  • Its antioxidant properties offer a synergistic benefit in managing CHF, addressing oxidative stress.
  • Carvedilol represents an important advancement in CHF therapy due to its multifaceted mechanism of action.

More Related Videos

Extraction and Purification of Polyphenols from Freeze-dried Berry Powder for the Treatment of Vascular Smooth Muscle Cells In Vitro12:00

Extraction and Purification of Polyphenols from Freeze-dried Berry Powder for the Treatment of Vascular Smooth Muscle Cells In Vitro

Published on: July 5, 2017

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers14:03

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers

Published on: March 24, 2023

Related Concept Videos

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...